Search

everythinglearnresearchcommunity

for

Search:↓

Customized medications made through compounding can be beneficial for various skin conditions but require careful regulation and collaboration between doctors and pharmacists.

The document concludes that more research is needed to include new treatments in guidelines for Polycystic Ovary Syndrome (PCOS).

The document concludes that scalp conditions have various causes and can present in many different ways.

AKR1C3 could be a treatment target for metabolic issues in PCOS.

The document concludes that treatments for female hair loss and excess body hair are available, but managing expectations is important.

Mycophenolic acid may help hair growth, a combination treatment improves hair thickness in male hair loss, and early treatment of frontal fibrosing alopecia is important.

Healthy aging can be promoted through physical activity, lifestyle changes, and certain treatments.

Pattern baldness is likely caused by a dominant gene influenced by testosterone levels, making it more common in men.

Cosmetic hair treatments can increase hair testosterone levels, while natural hair color does not affect it.

Androgens significantly affect female hair loss, and hormonal treatments may help.

Female pattern hair loss diagnosis is challenging and should use dermoscopy and histopathology instead of pattern recognition, as hormones may not always be the cause.

The document concludes that managing skin conditions during pregnancy is important and requires specialized care.

The conclusion is that PCOS is caused by ovarian sensitivity to hormones and disrupted hormone control, possibly due to ovarian factors, and more research is needed.

The document concludes that proper diagnosis and FDA-approved treatments for different types of hair loss exist, but treatments for severe cases often fail and future improvements may focus on hair follicle stem cells.

SHBG may be a useful early indicator and treatment target for PCOS.

Reproductive factors can increase hypertension risk and affect cardiovascular health.

Oestrogen and thyrotropin-releasing hormone affect prolactin and its receptor in human skin and hair, suggesting new treatment options for related conditions.

DHT's role in hair loss is important, but measuring its level for diagnosis is questionable.

The study concluded that both estrogen and androgen receptors, which decrease with age, are linked to skin aging and may be hormonally regulated.

Spironolactone is a low-cost, effective, and generally safe treatment for various skin conditions related to hormones.

The document concludes that sex hormones are crucial for mammalian reproduction, health, and behavior, and require more research for therapeutic use.

Chemotherapy patients don't all lose their hair due to factors like hair growth rates, age, genetics, and the type of drugs used.

Venous catheterization may help diagnose the cause of female hyperandrogenism when imaging is unclear.

Ancient hair can preserve hormones, revealing health and fertility insights.

Gender affects hair and scalp characteristics, with differences in hormone responses, graying patterns, and trace metals.

Platelet Rich Plasma can potentially help in restoring hair loss, but more research with larger groups is needed to confirm its effectiveness and standardize its use.

Aging scalp skin contributes to hair aging and loss, and more research is needed to develop better hair loss treatments.

The document concludes that diagnosing and treating hair loss is complex and requires understanding its psychological effects and underlying causes, while also calling for more research and new treatments.

FAPD and possibly CCCA may be AGA subtypes, and treatments combining antiandrogens, hair growth agents, hair transplants, and anti-inflammatories could be effective.

Testing for CAG repeat polymorphism in the androgen receptor gene is not currently recommended for managing hypogonadism.